Wistuba II - Search Results

1

Genetic Deletion of Galectin-3 Inhibits Pancreatic Cancer Progression and Enhances the Efficacy of Immunotherapy.

Yang D, Sun X, Moniruzzaman R, Wang H, Citu C, Zhao Z, Wistuba II, Wang H, Maitra A, Chen Y. Yang D, et al. Among authors: wistuba ii. Gastroenterology. 2024 Mar 11:S0016-5085(24)00288-9. doi: 10.1053/j.gastro.2024.03.007. Online ahead of print. Gastroenterology. 2024. PMID: 38467382

2

Minimally invasive genomic and transcriptomic profiling of visceral cancers by next-generation sequencing of circulating exosomes.

San Lucas FA, Allenson K, Bernard V, Castillo J, Kim DU, Ellis K, Ehli EA, Davies GE, Petersen JL, Li D, Wolff R, Katz M, Varadhachary G, Wistuba I, Maitra A, Alvarez H. San Lucas FA, et al. Ann Oncol. 2016 Apr;27(4):635-41. doi: 10.1093/annonc/mdv604. Epub 2015 Dec 17. Ann Oncol. 2016. PMID: 26681674 Free PMC article.

3

High prevalence of mutant KRAS in circulating exosome-derived DNA from early-stage pancreatic cancer patients.

Allenson K, Castillo J, San Lucas FA, Scelo G, Kim DU, Bernard V, Davis G, Kumar T, Katz M, Overman MJ, Foretova L, Fabianova E, Holcatova I, Janout V, Meric-Bernstam F, Gascoyne P, Wistuba I, Varadhachary G, Brennan P, Hanash S, Li D, Maitra A, Alvarez H. Allenson K, et al. Ann Oncol. 2017 Apr 1;28(4):741-747. doi: 10.1093/annonc/mdx004. Ann Oncol. 2017. PMID: 28104621 Free PMC article.

4

METTL13 Methylation of eEF1A Increases Translational Output to Promote Tumorigenesis.

Liu S, Hausmann S, Carlson SM, Fuentes ME, Francis JW, Pillai R, Lofgren SM, Hulea L, Tandoc K, Lu J, Li A, Nguyen ND, Caporicci M, Kim MP, Maitra A, Wang H, Wistuba II, Porco JA Jr, Bassik MC, Elias JE, Song J, Topisirovic I, Van Rechem C, Mazur PK, Gozani O. Liu S, et al. Among authors: wistuba ii. Cell. 2019 Jan 24;176(3):491-504.e21. doi: 10.1016/j.cell.2018.11.038. Epub 2019 Jan 3. Cell. 2019. PMID: 30612740 Free PMC article.

5

Immuno-profiling and cellular spatial analysis using five immune oncology multiplex immunofluorescence panels for paraffin tumor tissue.

Parra ER, Ferrufino-Schmidt MC, Tamegnon A, Zhang J, Solis L, Jiang M, Ibarguen H, Haymaker C, Lee JJ, Bernatchez C, Wistuba II. Parra ER, et al. Among authors: wistuba ii. Sci Rep. 2021 Apr 19;11(1):8511. doi: 10.1038/s41598-021-88156-0. Sci Rep. 2021. PMID: 33875760 Free PMC article.

6

Immune cellular patterns of distribution affect outcomes of patients with non-small cell lung cancer.

Parra ER, Zhang J, Jiang M, Tamegnon A, Pandurengan RK, Behrens C, Solis L, Haymaker C, Heymach JV, Moran C, Lee JJ, Gibbons D, Wistuba II. Parra ER, et al. Among authors: wistuba ii. Nat Commun. 2023 Apr 25;14(1):2364. doi: 10.1038/s41467-023-37905-y. Nat Commun. 2023. PMID: 37185575 Free PMC article.

7

A Pan-Cancer Analysis of Enhancer Expression in Nearly 9000 Patient Samples.

Chen H, Li C, Peng X, Zhou Z, Weinstein JN; Cancer Genome Atlas Research Network; Liang H. Chen H, et al. Cell. 2018 Apr 5;173(2):386-399.e12. doi: 10.1016/j.cell.2018.03.027. Cell. 2018. PMID: 29625054 Free PMC article.

8

Pathological Response and Immune Biomarker Assessment in Non-Small-Cell Lung Carcinoma Receiving Neoadjuvant Immune Checkpoint Inhibitors.

Rojas F, Parra ER, Wistuba II, Haymaker C, Solis Soto LM. Rojas F, et al. Among authors: wistuba ii. Cancers (Basel). 2022 Jun 2;14(11):2775. doi: 10.3390/cancers14112775. Cancers (Basel). 2022. PMID: 35681755 Free PMC article. Review.

9

The immune landscape of undifferentiated pleomorphic sarcoma.

Lazcano R, Barreto CM, Salazar R, Carapeto F, Traweek RS, Leung CH, Gite S, Mehta J, Ingram DR, Wani KM, Vu KT, Parra ER, Lu W, Zhou J, Witt RG, Cope B, Thirasastr P, Lin HY, Scally CP, Conley AP, Ratan R, Livingston JA, Zarzour AM, Ludwig J, Araujo D, Ravi V, Patel S, Benjamin R, Wargo J, Wistuba II, Somaiah N, Roland CL, Keung EZ, Solis L, Wang WL, Lazar AJ, Nassif EF. Lazcano R, et al. Among authors: wistuba ii. Front Oncol. 2022 Oct 12;12:1008484. doi: 10.3389/fonc.2022.1008484. eCollection 2022. Front Oncol. 2022. PMID: 36313661 Free PMC article.

10

PD-L1⁺ macrophages are associated with favorable features in primary mediastinal (thymic) large B-cell lymphoma.

Steiner RE, Parra ER, Vega F, Feng L, Westin JR, Neelapu SS, Strati P, Green MR, Flowers CR, Solis LM, Wistuba II, Ahmed S, Nair R, Hagemeister FB, Noorani M, Marques-Piubelli ML. Steiner RE, et al. Among authors: wistuba ii. Exp Hematol Oncol. 2023 Mar 20;12(1):32. doi: 10.1186/s40164-023-00396-0. Exp Hematol Oncol. 2023. PMID: 36941707 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

618 results

Search Page